β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer

被引:86
|
作者
Blandin, Anne-Florence [1 ]
Renner, Guillaume [1 ]
Lehmann, Maxime [1 ]
Lelong-Rebel, Isabelle [1 ]
Martin, Sophie [1 ]
Dontenwill, Monique [1 ]
机构
[1] Univ Strasbourg, Dept Tumoral Signaling & Therapeut Targets, CNRS, Fac Pharm,UMR7213, Illkirch Graffenstaden, France
来源
关键词
integrins; hallmarks of cancer; proliferation; migrationinvasion; resistance to cell death; angiogenesis; therapeutic target; SQUAMOUS-CELL CARCINOMA; INTEGRIN-LINKED KINASE; ALPHA-5-BETA-1; INTEGRIN; ALPHA-2-BETA-1; ANTIANGIOGENIC THERAPY; ANOIKIS RESISTANCE; SIGNALING PATHWAY; ADHESION KINASE; GROWTH-FACTORS; TUMOR-GROWTH;
D O I
10.3389/fphar.2015.00279
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Integrins belong to a large family of alpha beta heterodimeric transmembrane proteins first recognized as adhesion molecules that bind to dedicated elements of the extracellular matrix and also to other surrounding cells. As important sensors of the cell microenvironment, they regulate numerous signaling pathways in response to structural variations of the extracellular matrix. Biochemical and biomechanical cues provided by this matrix and transmitted to cells via integrins are critically modified in tumoral settings. lntegrins repertoire are subjected to expression level modifications, in tumor cells, and in surrounding cancer-associated cells, implicated in tumor initiation and progression as well. As critical players in numerous cancer hallmarks, defined by Hanahan and Weinberg (2011), integrins represent pertinent therapeutic targets. We will briefly summarize here our current knowledge about integrin implications in those different hallmarks focusing primarily on beta 1 integrins.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Alpha-v integrins as therapeutic targets in oncology
    Nemeth, Jeffrey A.
    Nakada, Marian T.
    Trikha, M.
    Lang, Zhihui
    Gordon, Michael S.
    Jayson, Gordon C.
    Corringham, Robert
    Prabhakar, Uma
    Davis, Hugh M.
    Beckman, Robert
    CANCER INVESTIGATION, 2007, 25 (07) : 632 - 646
  • [22] Vascular integrins in tumor angiogenesis:: Mediators and therapeutic targets
    Alghisi, Gian Carlo
    Rueegg, Curzio
    ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH, 2006, 13 (02): : 113 - 135
  • [23] Cancer Hallmarks and MicroRNAs: The Therapeutic Connection
    Van Roosbroeck, Katrien
    Calin, George A.
    MIRNA AND CANCER, 2017, 135 : 119 - 149
  • [24] Integrins: players in cancer progression and targets in cancer therapy
    Sun, Cui-Cui
    Qu, Xian-Jun
    Gao, Zu-Hua
    ANTI-CANCER DRUGS, 2014, 25 (10) : 1107 - 1121
  • [25] Integrins: roles in cancer development and as treatment targets
    Jin, H
    Varner, J
    BRITISH JOURNAL OF CANCER, 2004, 90 (03) : 561 - 565
  • [26] Integrins: roles in cancer development and as treatment targets
    H Jin
    J Varner
    British Journal of Cancer, 2004, 90 : 561 - 565
  • [27] Cancer Physical Hallmarks as New Targets for Improved Immunotherapy
    Guo, Hui
    Zhang, Tian
    Yu, Yang
    Xu, Feng
    TRENDS IN CELL BIOLOGY, 2021, 31 (07) : 520 - 524
  • [28] Integrins in cancer: Emerging mechanisms and therapeutic opportunities
    Liu, Fangfang
    Wu, Qiong
    Dong, Zigang
    Liu, Kangdong
    PHARMACOLOGY & THERAPEUTICS, 2023, 247
  • [29] TUMOR MICROENVIRONMENT AND INTEGRINS AS EFFECTIVE THERAPEUTIC TARGETS TO IMPROVE RADIOTHERAPY OUTCOME
    Wang, L.
    Valdecanas, D.
    Molkentine, D.
    Milas, L.
    Mason, K.
    Ang, K. K.
    Goodman, S. L.
    Raju, U.
    RADIOTHERAPY AND ONCOLOGY, 2012, 102 : S165 - S166
  • [30] Integrins in cancer: biological implications and therapeutic opportunities
    Jay S. Desgrosellier
    David A. Cheresh
    Nature Reviews Cancer, 2010, 10 : 9 - 22